𝔖 Bobbio Scriptorium
✦   LIBER   ✦

hsa-miR-210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer

✍ Scribed by Harriet E. Gee; Carme Camps; Francesca M. Buffa; Shalini Patiar; Stuart C. Winter; Guy Betts; Jarrod Homer; Rogan Corbridge; Graham Cox; Catharine M. L. West; Jiannis Ragoussis; Adrian L. Harris

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
289 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND:

Hypoxia is an important mechanism of treatment resistance in head and neck squamous cell carcinoma (HNSCC). MicroRNAs are short noncoding RNAs that regulate multiple mRNAs and are frequently dysregulated in cancer. The authors have investigated the role of 3 microRNAs, including the hypoxia‐induced hsa‐miR‐210, as potential markers of hypoxia or prognosis.

METHODS:

Three hypoxia‐related microRNAs, hsa‐miR‐210, hsa‐miR‐21, and hsa‐miR‐10b, were measured in 46 samples from patients with HNSCC. Expression levels were correlated with clinicopathological variables and other markers of hypoxia: a published 99‐gene hypoxia metagene, individual hypoxia‐related genes such as TWIST1, and immunohistochemical expression of hypoxia‐inducible factor 1 and its target gene carbonic anhydrase 9. We then performed survival analyses to investigate the prognostic significance of these microRNAs.

RESULTS:

Only the level of hsa‐miR‐210 was significantly correlated with other markers of hypoxia, including the 99‐gene hypoxia metagene (rho = 0.67, P < .001). We found no association between hsa‐miR‐210, hsa‐miR‐21, or hsa‐miR‐10b and clinicopathological variables such as tumor size, differentiation, and stage. However, high levels of hsa‐miR‐210 were associated with locoregional disease recurrence (P = .001) and short overall survival (P = .008). hsa‐miR‐21 and hsa‐miR‐10b had no prognostic significance.

CONCLUSIONS:

Expression of hsa‐miR‐210 in head and neck cancer correlates with other approaches for assessing hypoxia and is associated with prognosis. This warrants further study as a classification marker of patients for therapies involving modulation of hypoxia. Cancer 2010. © 2010 American Cancer Society.

📜 SIMILAR VOLUMES

Tumor volume as prognostic factor in che
Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer
✍ Joost L. Knegjens; Michael Hauptmann; Frank A. Pameijer; Alfons J. Balm; Frank J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

## Abstract ## Background Tumor volume is an important predictor of outcome in radiotherapy alone. Its significance in concomitant chemoradiation (CCRT) is much less clear. We analyzed the prognostic value of primary tumor volume for advanced head and neck squamous cell carcinoma (HNSCC) treated w

Proliferation index as a prognostic mark
Proliferation index as a prognostic marker in hemangiopericytoma of the head and neck
✍ Paul J. Kowalski; Augusto F. G. Paulino 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

## Abstract ## Background Hemangiopericytoma (HPC) of the head and neck is a rare neoplasm whose biologic behavior is difficult to predict by means of conventional histologic parameters. ## Methods H & E–stained sections from 12 cases of HPC were reviewed. Proliferation index was assessed using

Loss of heterozygosity on chromosome 2q:
Loss of heterozygosity on chromosome 2q: Possibly a poor prognostic factor in head and neck cancer
✍ David T. Ransom; Timothy C. Barnett; Joan Bot; Bastiaan de Boer; Cecily Metcalf; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

Background. Loss of heterozygosity (LOH) correlates with inactivated tumor suppressor genes. The aim of this study was to see if LOH on chromosomes 2q, 3p, 5q, 9p, and 17p correlated with survival in early squamous cell carcinoma of the head and neck (SCCHN). Methods. A case control study was perfo

Recurrence at the primary site in head a
Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor
✍ Charles R. Leemans; Rammohan Tiwari; Jos J. P. Nauta; Isaac Van Der Waal; Gordon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB 👁 2 views

Background. Biologic aggressiveness of head and neck carcinoma is reflected in its capability to metastasize to regional lymph nodes and its propensity to recur after treatment. Methods. The authors report on 244 patients treated at the Department of Otolaryngology-Head and Neck Surgery of the Free

Pretreatment FDG-PET standardized uptake
Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer
✍ Mitchell Machtay; Mona Natwa; Jocelyn Andrel; Terry Hyslop; P. Rani Anne; Jorors 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## Background. We studied the potential prognostic significance of pretreatment 18‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) standardized uptake value (SUV) in squamous cell carcinoma of the head and neck (SCCHN). ## Methods. A retrospective review of the pretreatment

Frequency of cells expressing CD44, a He
Frequency of cells expressing CD44, a Head and Neck cancer stem cell marker: Correlation with tumor aggressiveness
✍ Benzion Joshua; Michael J. Kaplan; Ilana Doweck; Reetesh Pai; Irving L. Weissman 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 1 views

## Abstract ## Background We previously identified by flow cytometry a Lineage‐CD44+ (Lin‐CD44+) subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma (HNSCC). We now correlate clinical and histologic factors with Lin‐CD44+ cell frequency. ## Methods Th